Compare CVGW & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVGW | OCGN |
|---|---|---|
| Founded | 1924 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Foods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 479.9M | 492.5M |
| IPO Year | 2002 | 2014 |
| Metric | CVGW | OCGN |
|---|---|---|
| Price | $26.61 | $1.39 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $33.50 | $9.75 |
| AVG Volume (30 Days) | 321.7K | ★ 7.5M |
| Earning Date | 06-08-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.85% | N/A |
| EPS Growth | ★ 1950.00 | 31.58 |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $648,434,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,718.38 |
| P/E Ratio | $670.00 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $18.40 | $0.73 |
| 52 Week High | $28.98 | $2.73 |
| Indicator | CVGW | OCGN |
|---|---|---|
| Relative Strength Index (RSI) | 40.34 | 34.84 |
| Support Level | $25.41 | $1.35 |
| Resistance Level | $26.86 | $1.92 |
| Average True Range (ATR) | 0.47 | 0.09 |
| MACD | -0.22 | -0.02 |
| Stochastic Oscillator | 1.87 | 1.92 |
Calavo Growers Inc is engaged in the sourcing, packing, and distribution of fresh avocados, tomatoes, and papayas, and the processing of guacamole and other avocado products. The company delivers products to retail grocers, club and mass-merchandise stores, foodservice operators, and wholesalers, sourcing avocados from California, Mexico, and other key growing regions. Its operations include sorting, packing, ripening, and shipping fresh produce, and processing and packaging fresh and frozen guacamole. The company operates through two segments: Fresh, including avocados, tomatoes, papayas, and other fresh produce products, and Prepared, including guacamole and avocado pulp, with the majority of revenue generated from the Fresh segment and geographically from the United States.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").